- Companies
- Alloy Therapeutics
Alloy Therapeutics Valuation, Funding & Investors
Alloy Therapeutics is valued at $1B as of April 2026.
Last Alloy Therapeutics valuation
$1B
Series E · Apr 2026
Last Alloy Therapeutics funding round
$40M
Series E · Apr 2026
Cumulative funding Alloy Therapeutics raised
$168M
across 4 funding rounds
Key investors in Alloy Therapeutics
8VC
Presight Capital
Founders Fund
Bossa Invest
Gaingels
Alexandria Venture Investments
About Alloy Therapeutics
Alloy Therapeutics is a platform democratizing access to drug discovery tools, starting with Alloy-Gx, a royalty-free suite of transgenic mice for human antibody discovery. Founded in 2017 and headquartered in Waltham, Massachusetts, it partners with biopharma companies to accelerate immunology research. The firm expands foundational platforms across modalities for faster therapeutic development.
Founded
2017
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Licensing
Valuation
$1B (Apr 2026)
Alloy Therapeutics Valuation
Alloy Therapeutics is currently valued at $1B, based on its Series E in April 2026.
The $40M round included JIC Venture Growth Investments, 8VC, Alexandria Venture Investments, Thiel Capital, Ulysses Holdings and 5 other investors.
Alloy Therapeutics' valuation has grown 1.8x from $563M at its Series C in April 2021 to $1B in April 2026, across 2 priced rounds.
Alloy Therapeutics valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Apr 2026 | Series E | $1B |
| Apr 2021 | Series C | $563M |
Alloy Therapeutics Funding History
Alloy Therapeutics has raised a total of $168M across 4 funding rounds.
Alloy Therapeutics' first fundraising round was a $11M Series B in June 2020. The most recent completed round was a $40M Series E in April 2026.
Alloy Therapeutics funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Apr 2026 | Series E | JIC Venture Growth Investments; 8VC; Alexandria Venture Investments; Thiel Capital; Ulysses Holdings; Founders Fund; Echo Capital; Mubadala Capital; Presight Capital; Gaingels | $40M | $1B | - |
| Oct 2022 | Series D | 8VC (lead); Mubadala (lead); Thiel Capital; Founders Fund; Presight Capital | $42M | - | Alloy Therapeutics is a Boston-based biotechnology ecosystem company that provides pre-competitive drug discovery technologies and services, including the Alloy platform for biologics discovery, initially focused on antibodies and expanded to TCRs and genetic medicines. It aims to democratize access to advanced discovery tools for biotech and pharma companies through collaborative models, reinvesting 100% of revenue into innovation and sharing new technologies with the community. The company also supports startups via its 82VS venture studio, providing early funding like million-dollar seed checks to promising projects with drug leads. On October 3, 2022, Alloy Therapeutics raised $42 million in a Series D funding round led by 8VC and Mubadala Capital Ventures, with participation from Founders Fund, Presight Capital, Thiel Capital, CM Capital, NFX, and undisclosed investors. This brought total funding to approximately $117 million across multiple rounds, following a $75 million Series C in April 2021 led by similar investors including 8VC, Presight Capital, and Peter Thiel. Proceeds from the Series D were intended to support the drug discovery community with new pre-competitive technologies in biologic modalities and innovative partnership models to fuel further innovation. Traction includes collaborations with big pharma and emerging biotechs, expansion of services, and portfolio investments in companies like Wheeler Bio ($80M raised). Competitively, Alloy positions itself as a lean alternative to large VC-backed model companies like those from Flagship, Atlas, or Third Rock Ventures, focusing on accessible, data-driven projects for Series A or seed financing. Post-round developments include acquisitions like deepCDR Biologics in December 2021 and ongoing portfolio growth into 2024 with companies like Aakha.bio and Voro Therapeutics. |
| Apr 2021 | Series C | 8VC (lead); Peter Thiel (lead); Presight Capital (lead); Alexandria Venture Investments; Ulysses Holdings; Founders Fund; Gaingels; Mubadala; Luma Bio-IT; Bossa Invest | $75M | $563M | Alloy Therapeutics is a biotechnology company based in Boston, Massachusetts dedicated to democratizing access to drug discovery and development platforms and services. The company operates as an ecosystem providing platforms for antibody therapeutics, T-cell receptor technologies, and antisense oligonucleotide development through its proprietary AntiClastic platform, while reinvesting 100% of revenue back into innovation and access initiatives. By October 2022, Alloy had raised an additional Series D round of $42 million, bringing total disclosed funding to at least $117 million. |
| Jun 2020 | Series B | 8VC (lead); Presight Capital; Bossa Invest | $11M | - | - |
Who has invested in Alloy Therapeutics?
14 investors have backed Alloy Therapeutics across its funding rounds, including 8VC, Presight Capital, Founders Fund, Bossa Invest, Gaingels and Alexandria Venture Investments.
Lead investors include 8VC, Mubadala, Peter Thiel and Presight Capital.
Alloy Therapeutics Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 4 | Lead | Jun 2020 | ||
| 4 | Lead | Jun 2020 | ||
| 3 | Participant | Apr 2021 | ||
| 2 | Participant | Apr 2021 | ||
| 2 | Participant | Oct 2022 | ||
| 2 | Participant | Apr 2021 | ||
| 2 | Participant | Apr 2021 | ||
| 2 | Lead | Apr 2021 | ||
| 2 | Participant | Jun 2020 | ||
| 1 | Participant | Apr 2026 | ||
| 1 | Lead | Apr 2021 | ||
| 1 | Participant | Apr 2026 | ||
This data is available for Pro users. Sign up to see all 14 Alloy Therapeutics investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Alloy Therapeutics
Alloy Therapeutics has acquired 2 companies to date.
Last acquisition by Alloy Therapeutics was on October 23rd 2025. Alloy Therapeutics acquired Spannerwerks for undisclosed valuation.
Latest Acquisitions by Alloy Therapeutics
| Description | Spannerwerks is a consortium of pharmaceutical experts based in the United States, offering end-to-end services for drug and biologic development from preclinical stages through commercialization. The network covers formulation, regulatory affairs, clinical trials, and manufacturing support for biotech firms. | deepCDR Biologics is a San Francisco-headquartered biotechnology firm developing AI platforms for computational antibody discovery. Its technology generates diverse CDR repertoires to design novel therapeutics against cancer and infectious diseases. The company offers end-to-end services from sequence design to preclinical validation, partnering with pharma companies for bispecific antibodies and CAR-T therapies. Founded in 2022, deepCDR leverages machine learning models trained on vast immune datasets. |
| HQ Country | ||
| HQ City | Seattle, WA | Basel |
| Deal Date | 23 Oct 2025 | 9 Dec 2021 |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Alloy Therapeutics acquisitions and their M&A valuation multiples. Start Free Trial | ||
Investments by Alloy Therapeutics
Alloy Therapeutics has invested in 3 companies to date.
Latest investment by Alloy Therapeutics was on March 20th 2025. Alloy Therapeutics invested in Wheeler Bio in their $35M Series A round.
Latest Investments by Alloy Therapeutics
| Description | Wheeler Bio is a biomanufacturing contract development and manufacturing organization headquartered in Oklahoma City. Launched in 2020, it offers an integrated platform accelerating drug development from discovery to Investigational New Drug applications. The company provides cell line development, process optimization, and GMP manufacturing for biologics, monoclonal antibodies, and gene therapies. Wheeler Bio's portable CMC services enable rapid scale-up for preclinical candidates, partnering with biotech firms nationwide. Its facilities feature single-use bioreactors up to 2000 liters, supporting Phase I clinical trials. | Wheeler Bio is a biomanufacturing contract development and manufacturing organization headquartered in Oklahoma City. Launched in 2020, it offers an integrated platform accelerating drug development from discovery to Investigational New Drug applications. The company provides cell line development, process optimization, and GMP manufacturing for biologics, monoclonal antibodies, and gene therapies. Wheeler Bio's portable CMC services enable rapid scale-up for preclinical candidates, partnering with biotech firms nationwide. Its facilities feature single-use bioreactors up to 2000 liters, supporting Phase I clinical trials. | Vernal Biosciences is a Boston-based biotech company producing high-purity mRNA for therapeutic development and clinical trials. The platform employs enzymatic capping and purification techniques to achieve over 95 percent purity levels. Vernal supplies custom sequences to pharmaceutical partners and supports IND-enabling studies. Facilities in Research Triangle Park handle scale-up manufacturing under GMP conditions. | Mytide Therapeutics is a peptide synthesis company that supplies custom peptides for drug discovery, research, and therapeutic applications. The platform enables partners to order peptides, calculate properties, track orders, and visualize data through its cloud-based system. Specializing in challenging peptide classes, modifications, and libraries, Mytide Therapeutics collaborates with biotech firms to accelerate development. Based in the United States, it serves academic labs and pharmaceutical companies worldwide via www.mytide.io. | |
| HQ Country | |||||
| HQ City | Oklahoma City, OK | Oklahoma City, OK | - | Boston, MA | |
| Deal Date | 20 Mar 2025 | 4 Oct 2022 | 2 Jun 2022 | 8 Mar 2022 | |
| Round | Series A | Series A | Series A | Series A | |
| Raised | $35M | $31M | $21M | $7M | |
| Investors | Echo Investment Capital; Mitsubishi Corporation (Americas); Germin8 Ventures; Russell Westbrook Enterprises | Charles River; Seagull Capital; Pine Ridge Ventures; Echo Investment Capital; Plains Ventures; ATUM | Charles River; Dynamk Capital; ATUM; Ampersand Capital Partners | Uncommon Denominator; Trog Hawley Capital | |
| Valuation | undisclosed | undisclosed | undisclosed | $35M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Alloy Therapeutics investments and their VC round multiples. Start Free Trial | |||||
Alloy Therapeutics Competitors
Alloy Therapeutics competitors include listed companies like Maravai LifeSciences, R&G PharmaStudies, Aurisco Pharmaceutical and Akums Drugs and Pharma, and private ones like VectorBuilder and Letu.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $1B | - | ||
| Publicly listed | $186M | ($159M) | $1.1B | 6.6x | ||
| Private | - | - | $1.1B | - | ||
| Publicly listed | $127M | $27M | $901M | 4.7x | ||
| Publicly listed | $253M | $99M | $1.2B | 4.8x | ||
| Publicly listed | $443M | $54M | $1.2B | 2.2x |
Alloy Therapeutics Public Comps
Alloy Therapeutics is still privately-owned, but its public comps include Maravai LifeSciences, R&G PharmaStudies, Aurisco Pharmaceutical, Sirio Pharma Co, Akums Drugs and Pharma, Aarti Pharmalabs, Gubra, Oxford BioMedica, ST Pharm and Anupam Rasayan India.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $186M | ($159M) | 7.2x | 6.6x | (8.4x) | 87.7x | |||
| $127M | $27M | 5.2x | 4.7x | 24.2x | 21.2x | |||
| $253M | $99M | 4.8x | 4.8x | 12.1x | 12.3x | |||
| $636M | $52M | 1.5x | 1.5x | 18.3x | 8.9x | |||
| $443M | $54M | 2.4x | 2.2x | 19.9x | 16.6x | |||
| $186M | $40M | 4.6x | - | 21.4x | - | |||
| $406M | $331M | 1.5x | 3.4x | 1.9x | 6.1x | |||
| $227M | ($4M) | 3.5x | 3.1x | (214.9x) | 78.3x | |||
This data is available for Pro users. Sign up to see all Alloy Therapeutics competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Alloy Therapeutics
| When was Alloy Therapeutics founded? | Alloy Therapeutics was founded in 2017. |
| Where is Alloy Therapeutics headquartered? | Alloy Therapeutics is headquartered in Boston, MA, United States. |
| Is Alloy Therapeutics publicly listed? | No, Alloy Therapeutics is a private, VC-backed company. |
| What is Alloy Therapeutics' valuation? | Alloy Therapeutics was last valued at $1B in its Series E in April 2026. |
| How much funding has Alloy Therapeutics raised? | Alloy Therapeutics has raised $168M across 4 funding rounds. |
| What was Alloy Therapeutics' last funding round? | Alloy Therapeutics' last funding round was a $40M Series E in April 2026. |
| Who are Alloy Therapeutics' investors? | Alloy Therapeutics' investors include 8VC, Presight Capital, Founders Fund, Alexandria Venture Investments, Thiel Capital, Ulysses Holdings, Gaingels, Mubadala, Bossa Invest, JIC Venture Growth Investments and 4 others. |
| Which companies are comparable to Alloy Therapeutics? | Companies comparable to Alloy Therapeutics include VectorBuilder, Maravai LifeSciences, Letu, R&G PharmaStudies, Aurisco Pharmaceutical and Akums Drugs and Pharma. |
| How many companies has Alloy Therapeutics acquired? | Alloy Therapeutics has acquired 2 companies, including Spannerwerks and deepCDR Biologics. |
| How many companies has Alloy Therapeutics invested in? | Alloy Therapeutics has invested in 3 companies, including Wheeler Bio, Vernal Biosciences and Mytide Therapeutics. |
| What was Alloy Therapeutics' last investment? | In March 2025, Alloy Therapeutics invested in Wheeler Bio's $35M Series A alongside Echo Investment Capital, Mitsubishi Corporation (Americas), Germin8 Ventures and 1 other investor. |
See companies similar to Alloy Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




